09688 ZAI LAB
- 12.540
- -0.080-0.63%
ZAI LAB News
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Buy Rating Affirmed for Zai Lab Amid Strong Sales Performance and Positive Development Outlook
Zaiding Pharmaceutical (9688.HK): Performance is in line with expectations, and Agamod is expected to be released
Citigroup Maintains Buy on Zai Lab, Lowers Price Target to $66
Zai Lab Analyst Ratings
Buy Rating on Zai Lab With a Target Price of $66 Amid Vyvgart's Growth Potential and Strategic Positioning
Buy Rating Affirmed for Zai Lab on Strong Product Performance and Upbeat Revenue Projections
Zai Lab's Growth and Pipeline Prompts Buy Rating: Analyst David Li's Financial Outlook and Price Objective
Zaiding Pharmaceutical (9688.HK): Accelerating the commercialization process and promoting profit prospects to maintain a “buy” rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Globus Medical (GMED) and Zai Lab (ZLAB)
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Zai Lab (ZLAB)
Morgan Stanley Initiates Coverage On Zai Lab With Overweight Rating, Announces Price Target of $47.5
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
Zai Lab's Strong Sales Performance and Market Dominance Bolsters Buy Rating: An Analysis by David Li
Analysts Are Bullish on These Technology Stocks: Zai Lab (ZLAB), Navitas Semiconductor (NVTS)
Analysts Conflicted on These Technology Names: AUTO1 Group SE (OtherATOGF), Rivian Automotive (RIVN) and Zai Lab (ZLAB)
Analysts Offer Insights on Technology Companies: Klaviyo, Inc. Class A (KVYO), Zai Lab (ZLAB) and Mobileye Global, Inc. Class A (MBLY)
Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating
Goldman Sachs Maintains Buy on Zai Lab, Lowers Price Target to $73.34
Analysis
Price Target
No Data
